Ple{NTY} of Reasons to Take Your Vitamins

Ockham Research Staff @ October 16, 2008 # No Comment Yet


NBTY, formerly known as Nature’s Bounty, (Symbol: NTY) reported healthy sales gains for the quarter just ended. However, the stock took a dive after those quarterly results failed to live up to estimates. So, NBTY looks to be Undervalued, but we remain cuatious in this investing environment because overall market action is still decidedly negative.

More on this topic (What's this?)
Down an Unsustainable Path
Philips Electronics (PHG) Stock Dividend Analysis
Health Care Costs Shifting
Read more on NBTY, Pharma & Healthcare at Wikinvest

More on: Ple{NTY} of Reasons to Take Your Vitamins

Johnson & Johnson Staying Healthy

Ockham Research Staff @ October 14, 2008 # No Comment Yet


Johnson & Johnson reported better than expected performance in the quarter just ended. Sales growth was solid and management did a great job managing the company through a difficult environment. If you are looking to pull back into a more defensive stock that also has some upside potential, take a look at JNJ.

More on this topic (What's this?)
J&J, safe, solid, & consistent
Pharmas of the Dow.
The 424 Dividend Boost — 12% Letter
Read more on JOHNSON & JOHNSON at Wikinvest

More on: Johnson & Johnson Staying Healthy

Adhering to a Value Investing Strategy

Ockham Research Staff @ October 6, 2008 # No Comment Yet


It is not easy to be bullish right now, but sometimes being a contrarian is tough to stomach. However, it has been shown to work in the past if you have the discipline to adhere to the strategy.

More on this topic (What's this?)
40 Value Stocks that Graham Would Buy
Book Review: Margin of Safety
Does Value Investing Lead to Fraud?
Read more on Value Investing, S&P 500 at Wikinvest

More on: Adhering to a Value Investing Strategy

The EIG Newsletter Gets a Makeover

Ockham Research Staff @ September 30, 2008 # No Comment Yet


An overview of the changes to our newsletter and the announcement that coverage for all 100 equities covered on our Ockham Research web site will be avialable to the public for free. Please visit www.ockhamresearch.com to view these research reports.

More on: The EIG Newsletter Gets a Makeover

Quality Systems, Inc. is Poised to Continue Growth

Ockham Research Staff @ September 22, 2008 # 2 Comments


in this article we are highlighting a great mid-cap company in the Healthcare IT market. QSII has grown by leaps and bounds as the electrionic medical records (EMR) market has expanded greatly. The trend shows little signs of slowing and this stock may represent a good buy even though it is up more than 35% in the last 6 weeks.

More on this topic (What's this?)
Bookkeeping: Starting Quality Systems (QSII)
Emerson Electric: Heating Up?
Looking for Health(y) Returns
Read more on Quality Systems, Emerson Electric Company at Wikinvest

More on: Quality Systems, Inc. is Poised to Continue Growth

Abbott Labs Delivers Above Expectations

Ockham Research Staff @ July 16, 2008 # No Comment Yet


ABT Labs blew past earnings expectations as profit jumped 34%. We are reiterating our Buy rating as fundamentals have greatly improved and in a tough environment. This is a sign of exceptional management which is something we are always eager to find.

More on this topic (What's this?)
Abbott Laboratories (ABT) Dividend Analysis
Read more on Abbott Laboratories at Wikinvest

More on: Abbott Labs Delivers Above Expectations

Medtronic Beats Estimates

Ockham Research Staff @ May 20, 2008 # No Comment Yet


Medtronic (MDT) reported its fiscal fourth quarter (ended April 25) results prior to trading Tuesday morning. The medical device company reported flat net income from results a year ago that were aided by a tax gain. However, revenues rose by more than 18%, thanks in large part to the introduction of the Endeavor drug-dispensing stent. […]

More on this topic (What's this?)
The Beat Continues At Medtronic
Medtronic Hits My Radar
Bookkeeping: Adding to NuVasive (NUVA)
Read more on Medtronic at Wikinvest

More on: Medtronic Beats Estimates

Monday brings Heartburn for Schering-Plough

admin @ March 31, 2008 # No Comment Yet


It was a rough Monday morning for stock owners of Merck & Co. ( MRK) and Schering-Plough Corp. ( SGP) as a panel of cardiologists recommended that Doctors sharply reduce their prescribing of the companies’ jointly marketed cholesterol drugs Vytorin and Zetia. The cardiologists based their claim in the results […]

More on: Monday brings Heartburn for Schering-Plough

Take a Close Look at Amgen

admin @ February 4, 2008 # No Comment Yet


It was a relatively slow day for news coming out of the markets, and there is about as much coverage of Super Bowl commercials as anything else. Perhaps Wall Street is a little slow in recovering from a night of partying after the New York Giants pulled off the stunning upset […]

More on this topic (What's this?)
The Lights of Runaway Freight Trains
As Amgen sets new 52-week low, traders hunker down for downside
Health Care Costs Shifting
Read more on Amgen, Pharma & Healthcare at Wikinvest

More on: Take a Close Look at Amgen

Breaking News